+86 17357207897
搜索
News
你的位置:HomePage > News

Approved by the National Medical Products Administration for the Marketing of Didacinib Capsules

* Source: * Author: admin * Publication time: 2022/05/30 9:39:50 * Browse: 55

Recently, the National Medical Products Administration approved the listing of the Class 1 innovative drug, Dacinib capsules, applied by Zhejiang Jingxin Pharmaceutical Co., Ltd. This medicine is suitable for short-term treatment of patients with insomnia disorders.


Didaxinib belongs to the benzodiazepine class of drugs and is γ- Partial positive allosteric modulators of aminobutyric acid type A (GABAA) receptors produce sleep promoting effects by partially activating GABAA receptors. The launch of this drug provides a new treatment option for patients with insomnia disorders.